Search results
Unveiling Akebia Therapeutics (AKBA)'s Value: Is It Really Priced Right? A Comprehensive Guide
GuruFocus.com via Yahoo Finance· 9 months agoWith a daily gain of 15.57% and a 3-month gain of 13.19%, Akebia Therapeutics Inc (NASDAQ:AKBA) has...
Benign Growth For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Underpins Its Share Price
Simply Wall St. via Yahoo Finance· 1 year agoWith a price-to-sales (or "P/S") ratio of 0.4x Akebia Therapeutics, Inc. (NASDAQ:AKBA) may be...
Akebia Therapeutics (NASDAQ:AKBA) shareholders have earned a 265% return over the last year
Simply Wall St. via Yahoo Finance· 6 months agoIt hasn't been the best quarter for Akebia Therapeutics, Inc. (NASDAQ:AKBA) shareholders, since the...
Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been splendid, earning 188% in 1 year
Simply Wall St. via Yahoo Finance· 12 months agoThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the...
All You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy
Zacks via Yahoo Finance· 12 months agoAkebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which...
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Zacks via Yahoo Finance· 7 months agoAkebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a...
Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates
Zacks via Yahoo Finance· 2 years agoAkebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%,...
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Zacks via Yahoo Finance· 2 months agoAkebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets...
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 weeks agoAkebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript May 9, 2024 Akebia...
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Benzinga via Yahoo Finance· 2 years agoAkebia Therapeutics Inc (NASDAQ: AKBA) announced initial findings from an investigator-sponsored...